Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr
| Parent link: | Bioconjugate Chemistry.— .— Washington: ACS Publications Vol. 36, iss. 4.— 2025.— P. 748-761 |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , |
| Summary: | Title screen Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines Текстовый файл AM_Agreement |
| Language: | English |
| Published: |
2025
|
| Subjects: | |
| Online Access: | https://doi.org/10.1021/acs.bioconjchem.5c00033 |
| Format: | Electronic Book Chapter |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=680484 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 680484 | ||
| 005 | 20251223162631.0 | ||
| 090 | |a 680484 | ||
| 100 | |a 20250606d2025 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a US | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr |f Stanislav A. Petrov, Gleb P. Grigoriev, Grigory A. Orlov [et al.] | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 330 | |a Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines | ||
| 336 | |a Текстовый файл | ||
| 371 | 0 | |a AM_Agreement | |
| 461 | 1 | |t Bioconjugate Chemistry |c Washington |n ACS Publications | |
| 463 | 1 | |t Vol. 36, iss. 4 |v P. 748-761 |d 2025 | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 701 | 1 | |a Petrov |b S, F. |g Stanislav | |
| 701 | 1 | |a Grigoriev |b G. P. |g Gleb | |
| 701 | 1 | |a Orlov |b G. A. |g Grigory | |
| 701 | 1 | |a Zyk |b N. Y. |g Nikolay | |
| 701 | 1 | |a Grishin |b Yu. K. |g Yuri | |
| 701 | 1 | |a Roznyatovsky |b V. A. |g Vitaly | |
| 701 | 1 | |a Beloglazkina |b M. A. |g Maria | |
| 701 | 1 | |a Petrova |b J. P. |g Juliana | |
| 701 | 1 | |a Machulkin |b A. E. |g Aleksei | |
| 701 | 1 | |a Larkina |b M. S. |g Mariya Sergeevna |f 1984- |c pharmacist |c Professor; Senior Researcher of the Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences |9 22417 | |
| 701 | 1 | |a Prach |b A. A. |g Anastasiya Aleksandrovna |f 1999- |c chemist |c engineer of Tomsk Polytechnic University |y Tomsk |9 88930 | |
| 701 | 1 | |a Varvashenya |b R. N. |c pharmacist |c engineer at Tomsk Polytechnic University |f 1997- |g Ruslan Nikolaevich |9 88559 | |
| 701 | 1 | |a Bodenko |b V. V. |c pharmacist |c engineer at Tomsk Polytechnic University |f 1997- |g Vitalina Vasiljevna |9 88553 | |
| 701 | 1 | |a Plotnikov |b E. V. |c chemist |c Associate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences |f 1983- |g Evgeny Vladimirovich |9 16417 | |
| 701 | 1 | |a Yusubov |b M. S. |c chemist |c Professor of Tomsk Polytechnic University, Doctor of chemical sciences |f 1961- |g Mekhman Suleiman-Ogly (Suleimanovich) |9 15928 | |
| 801 | 0 | |a RU |b 63413507 |c 20250606 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.1021/acs.bioconjchem.5c00033 |z https://doi.org/10.1021/acs.bioconjchem.5c00033 | |
| 942 | |c CF | ||